SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences gains after India rating affirms its long-term issuer rating at ‘A+’

11 Dec 2013 Evaluate

Jubilant Life Sciences is currently trading at Rs. 119.55, up by 4.10 points or 3.55% from its previous closing of Rs. 115.45 on the BSE.

The scrip opened at Rs. 115.90 and has touched a high and low of Rs. 120.40 and Rs. 114.10 respectively. So far 54,000 shares were traded on the counter.

The BSE group 'B' stock of face value Re 1 has touched a 52 week high of Rs. 239.75 on 11-Nov-2012 and a 52 week low of Rs 65.10 on 28-Aug-2013.

Last one week high and low of the scrip stood at Rs 145.80 and Rs 114.10 respectively. The current market cap of the company is Rs 856 crore.

The promoters holding in the company stood at 53.95% while Institutions and Non-Institutions held 28.41% and 17.65% respectively.

Credit rating agency, India Ratings & Research has affirmed Jubilant Life Sciences’ long-term issuer rating at ‘A+’ with stable outlook. The affirmation reflects the company’s healthy business risk profile, supported by its strong domestic market position in custom research and manufacturing services coupled with its geographically diversified revenue streams.

Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.

As on September 30, 2013, Jubilant Life Sciences had a total of 676 filings for formulations of which 218 have been approved in various regions of the world. This includes 58 ANDAs filed in the US and 48 Dossier filings in Europe.

Jubilant Pharmova Share Price

973.45 3.70 (0.38%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×